QUANTITATIVE EVALUATION OF JAK2V617F MUTATION AND BCR-ABL P210 TRANSLOCATION IN PATIENTS WITH SIMULTANEOUS JAK2V617F MUTATION AND BCR-ABL TRANSLOCATION

A small number of patients showed simultaneous occurrence of both JAK2(V617F) mutation and BCR/ABL translocation. The problem is whether this simultaneous occurrence of molecular markers indicates the presence of two diseases Ph-negative myeloproliferative disease and Ph-positive myeloproliferative disease. We present two cases of simultaneous occurrence of both JAK2(V617F) mutation and BCR/ABL p210 translocation. Reduction of the BCR-ABL p210 transcript level to 0.29 and 0.014% in cases 1 and 2, respectively, was paralleled by increase of JAK2V617F level to 100% in the former case and its reduction to 5% and subsequent increase to 43% in the latter case.